The drug candidate BTZ-043 has a novel mechanism of action and belongs to a new class of substances. Discovered at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI
The INCubator for Antibacterial Therapies in Europe, INCATE, aims to support innovators in the early stages of developing therapies in the field of antimicrobial resistance. The German Center for
Please use this image only in connection with this press release.
The development of antibiotic resistance is increasingly complicating the treatment of tuberculosis. Patients suffering from multidrug-resistant tuberculosis (MDR-TB) are particularly hard hit. In
Children as well as HIV-positive adults often suffer from extrapulmonary tuberculosis (TB). Due to the low sensitivity of routine microbiological TB tests, it is often difficult to obtain confirmation of mycobacterial disease. Point-of-care ultrasound (POC-US) is becoming increasingly established as ...